Congratulations to Alba Therapeutics for Reporting Positive Phase IIb Trial Results
Tuesday, February 11, 2014
Alba Therapeutics Corporation announced on February 11, 2014, the positive results of its Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD). The study met its primary endpoint and, based on these results, Alba has initiated planning for Phase III clinical trials for the definitive assessment of the oral peptide's efficacy and safety. The final data will be submitted for publication in the near future.